OncoMatch/Clinical Trials/NCT06627270
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Is NCT06627270 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Metronidazole for oral squamous cell carcinoma.
Treatment: Metronidazole — The goal of this phase II single arm clinical study is to evaluate the effect of antibiotics (metronidazole) and oral chlorhexidine (CHX) in reducing the bacteria load within tumors of patients undergoing surgery for oral cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Prior therapy
Cannot have received: antibiotic
Participants currently or have taken other antibiotics within the prior 30 days
Cannot have received: radiation therapy
Recurrent oral cancer after prior radiation or chemoradiation
Cannot have received: chemoradiation
Recurrent oral cancer after prior radiation or chemoradiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify